A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
HOME > BUSINESS
BUSINESS
- Aspen Japan Commences Operations in Japan
June 5, 2015
- Takecab Ranks 1st for 4th Month Running in GP, HP Markets in April: Anterio Ranking
June 4, 2015
- Takeda to Set Up Global Vaccine Business Hub in US
June 4, 2015
- Highlights of FY2014 Earnings - Part 1: 35 Listed Drug Makers See Downtrend in Profits Despite 3% Sales Uptick
June 4, 2015
- MSD Transfers Marketing Rights for Claritin to Bayer Yakuhin
June 3, 2015
- Astellas, Anokion Join Hands on Immune Tolerance Therapeutics
June 3, 2015
- Merck Serono Names CFO Koji Okamoto as New President
June 2, 2015
- Former Merck Serono President Feliciano Becomes AbbVie G.K.’s New President
June 2, 2015
- Pfizer, Merck Serono Initiate Copromotion for Xalkori
June 2, 2015
- 14-Day Prescription Limit Lifted for Efient: Daiichi Sankyo
June 2, 2015
- Lenvima Receives European Approval: Eisai
June 2, 2015
- Meiji Seika Pharma Seeks Japan Approval for Asenapine
May 29, 2015
- Otsuka Wins EU Approval for ADPKD Drug Jinarc
May 29, 2015
- Eisai Files Ultra-High Dose Mecobalamin for ALS in Japan
May 29, 2015
- Takeda Launches Once-Weekly DPP-4 Inhibitor Zafatek
May 29, 2015
- Sanofi Files NDA for Antiepileptic Treatment Vigabatrin
May 29, 2015
- Astellas Confident about Achieving FY2017 Japan Sales Target
May 28, 2015
- Asahi Kasei’s New Midterm Plan Aims to Maintain Profitability and Expand Sales in Healthcare Field
May 28, 2015
- Fycompa Receives Positive Opinion from CHMP for Adjunct Therapy for PGTC Seizures: Eisai
May 28, 2015
- Sanofi Oncology Business Unit Head Pascal Rigaudy to Become New President of Genzyme Japan
May 28, 2015
ページ
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…